Institutional members access full text with Ovid®

Share this article on:

Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria

Agbaji, Oche MD*; Thio, Chloe L. MD; Meloni, Seema PhD, MPH; Graham, Camilla MD§; Muazu, Mohammed MSc*; Nimzing, Ladep MD; Idoko, John MD*; Sankalé, Jean-Louis PharmD, SD; Ekong, Ernest MD; Murphy, Robert MD; Kanki, Phyllis DVM, SD; Hawkins, Claudia MD, MPH

JAIDS Journal of Acquired Immune Deficiency Syndromes: February 1st, 2013 - Volume 62 - Issue 2 - p 204–207
doi: 10.1097/QAI.0b013e31827ce536
Brief Report: Clinical Science

Abstract: The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.

*Department of Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria

Department of Internal Medicine, Johns Hopkins University, Baltimore, MD

Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA

§Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

Division of Hepatology, Imperial College London, London, United Kingdom

Department of Medicine, Northwestern University, Chicago, IL. Dr J. Idoko is now with the National Agency for the Control of AIDS, Abuja, Nigeria.

Correspondence to: Oche Agbaji, MD, Department of Medicine, Jos University Teaching Hospital, P.M.B.2076, Jos, Nigeria (e-mail:

Supported by NIH U01 AI38858, the Northwestern University AIDS International Training and Research Program (NU-AITRP, Grant # 5D43TWOO7995-02, and Cooperative Agreement # U51HA02522 from the Health Resources and Services Administration). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Health Resources and Services Administration. C.T. was additionally supported by NIH grants R01AI071820 and R56AI060449. C.G. was additionally supported by the National Institutes of Health grant AACTG.51.PEPFAR.03 (CSG).

Presented in part at the 15th Conference on Retroviruses and Opportunistic Infections, February 3–6, 2008, Boston, MA. Abstract 1058.

The authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Received June 22, 2012

Accepted November 06, 2012

© 2013 Lippincott Williams & Wilkins, Inc.